4D Molecular Therapeutics (FDMT) AI Stock Analysis

• Market Cap: $167.15M
• Dividend Yield: N/A
• Average Volume (3M): 738.36K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.09
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 147
• Sector: Healthcare
• Sector Strength: 66
• Industry: Biotechnology
• EPS (TTM): -3.16
• Shares Outstanding: 46,302,406
• 10 Day Avg. Volume: 638,865
• 30 Day Avg. Volume: 738,361
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 4905.55
• Price to Cash Flow (P/CF): -1.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $33.40
• Price Target Upside: 825.21% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10

4D Molecular Therapeutics is currently facing substantial financial and technical challenges. The company's negative income and cash flow trends, alongside bearish technical indicators, contribute to a low overall stock score. While there are improvements in the balance sheet, the lack of consistent revenue and profitability, coupled with negative market momentum, pose significant risks. The valuation reflects typical early-stage biotech characteristics with a negative P/E ratio and no dividend yield.

Positive Factors

Clinical Advancements

The gene therapy program is on the verge of pivotal trial initiations, highlighting a significant advancement for the company.

Financial Health

FDMT ended the year with $505M in cash, which is expected to fund operations into 2028, providing a strong financial foundation for future developments.

Safety Profile

4D-150’s safety remains highly favorable with less than 3% of patients showing minimal inflammation and 99% remaining steroid-free.

Negative Factors

Commercial Dynamics

Analyst's rating is predicated primarily on currently difficult-to-discern eventual commercial dynamics for an anti-VEGF gene therapy.

Competition

There is competition from other programs and possible retina business model disruption.

Program Delays

4D-175, 4D-725, and 4D-310 remain paused pending additional financing or partnerships, indicating potential delays in these programs.

4D Molecular Therapeutics Business Overview & Revenue Model

Company Description

4D Molecular Therapeutics (FDMT) is a biotechnology company focused on developing precision-guided AAV gene therapy vectors and products. The company operates within the healthcare sector, specializing in the design, development, and commercialization of transformative gene therapies for patients with serious genetic diseases. Its core products are based on proprietary technology that enables targeted delivery and enhanced efficacy of gene therapies, aiming to address unmet medical needs across a range of therapeutic areas.

How the Company Makes Money

4D Molecular Therapeutics generates revenue through a combination of research and development collaborations, licensing agreements, and potential future product sales. The company partners with pharmaceutical and biotechnology firms to co-develop gene therapy solutions using its proprietary vector technology, which often involves upfront payments, milestone payments, and royalties on future sales. Additionally, the company may receive funding from grants and government programs aimed at advancing gene therapy research. As the company advances its pipeline and achieves regulatory approvals, future revenue is expected to come from the commercialization of its own gene therapy products.

4D Molecular Therapeutics Financial Statement Overview

Summary

4D Molecular Therapeutics faces significant financial challenges typical of the biotechnology sector, particularly in early-stage development without consistent revenue streams. The balance sheet shows improvement, but the negative income and cash flow trends highlight ongoing operational hurdles. Future success will rely heavily on successful research outcomes and continued access to financing.

Income Statement

The company has experienced erratic revenue trends with significant fluctuations over the years. The lack of revenue in 2024 compared to the previous year denotes a challenging operational environment. Negative net income has been persistent, showcasing difficulties in achieving profitability. Margins are negative, and although the company had some revenue growth in prior years, sustainability remains questionable.

Balance Sheet

The company's balance sheet shows a strong equity base due to significant cash holdings, which is a positive aspect. However, the company's financial stability is undermined by negative equity in previous years. Recent improvements in stockholders' equity and low debt levels indicate improving financial health, but past fluctuations present a risk.

Cash Flow

Cash flow from operations is consistently negative, reflecting ongoing cash burn typical of early-stage biotech companies. While free cash flow remains negative, the increase in financing activities suggests reliance on external funding to sustain operations. Positive trends in financing cash flow are countered by high levels of capital expenditure.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
37.00K	20.72M	3.13M	18.04M	13.61M
	Gross Profit
37.00K	-76.37M	-751.00K	15.02M	-39.43M
	EBIT
-187.84M	-112.87M	-110.03M	-71.33M	-56.66M
	EBITDA
-187.84M	-107.12M	-106.15M	-68.31M	-55.22M
	Net Income Common Stockholders
-160.87M	-100.84M	-101.08M	-68.30M	-56.54M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
424.88M	288.23M	218.64M	315.43M	276.73M
	Total Assets
560.38M	339.89M	261.85M	353.49M	288.33M
	Total Debt
24.61M	14.67M	16.12M	16.45M	0.00
	Net Debt
-124.73M	-234.44M	-202.52M	-298.98M	-276.73M
	Total Liabilities
49.78M	32.06M	30.51M	560.48M	31.94M
	Stockholders Equity
510.61M	307.83M	-314.49M	-207.00M	256.39M
Cash Flow		Free Cash Flow
-134.59M	-78.56M	-98.22M	-78.24M	-51.91M
	Operating Cash Flow
-134.59M	-75.79M	-86.69M	-69.13M	-50.91M
	Investing Cash Flow
-302.44M	115.72M	-17.05M	-172.68M	-1.00M
	Financing Cash Flow
337.25M	156.83M	3.08M	118.09M	278.98M

4D Molecular Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.61
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FDMT, the sentiment is Negative. The current price of 3.61 is below the 20-day moving average (MA) of 4.04, below the 50-day MA of 4.63, and below the 200-day MA of 10.89, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 34.41 is Neutral, neither overbought nor oversold. The STOCH value of 22.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FDMT.

4D Molecular Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	49 Neutral	$6.88B	0.82	-52.97%	2.48%	20.92%	1.17%
CRSP	46 Neutral	$3.36B	―	-19.20%	―	-89.95%	-123.71%
ADVM	42 Neutral	$104.84M	―	-76.26%	―	-72.22%	51.95%
SGMO	41 Neutral	$189.88M	―	-187.83%	―	-67.20%	64.66%
EDIT	39 Underperform	$107.87M	―	-98.10%	―	-58.64%	-40.05%
NTLA	39 Underperform	$860.23M	―	-54.00%	―	59.55%	3.09%
FDMT	35 Underperform	$167.15M	―	-25.95%	―	―	―